Introduction 41 million lives annually and the global number of TB cases is still rising at a rate of 0.6% per year 44 (26) . Approximately 2% of new tuberculosis cases in the world are attributed to multi-drug-45 resistant (MDR) strains, defined as M. tuberculosis isolates resistant to at least isoniazid and 46 rifampicin, the two most powerful anti-TB drugs. However, multi-drug resistance rates in some 47 countries, particularly in the former Soviet Union, Asia, the Dominican Republic and Argentina, 48 are much higher and may reach more than 22% of all isolates (16). Moreover, extensively drug 49 resistant (XDR) strains that are resistant to three or more of the six classes of second line drugs 50 in addition to rifampicin and isoniazid have been reported in all regions of the world (5) raising 51 the possibility of future epidemics of virtually untreatable forms of TB. The continuing rise in 52 disease incidence, the problem of drug resistance and the need to reduce treatment duration has 53 prompted research on new drug developments (11). In this light, the re-examination of Isoxyl 54 (ISO) (4,4'-diisoamyloxydiphenylthiourea; 4,4'-diisoamyloxythiocarbanilide; thiocarlide), a 55 thiourea derivative that was successfully used for the clinical treatment of TB during the 1960s, 56 may prove useful in identifying new therapeutic targets and in developing new therapeutic agents 57 with greater potency and more desirable features than earlier thioureas (1,14,21,23-24). 58 antibody (Penta-His antibody, Qiagen) (13). 151 weight) resuspended in 3 ml of buffer A (25 mM Tris-HCl, pH 7.5, 300 mM NaCl) were 155 disrupted by probe sonication for 8 min in the form of 60 s pulses with 90 s cooling intervals. 156
The sonicate was centrifuged for 5 min at 2,000 x g at 4°C and the supernatant from this 157 centrifugation was loaded onto a BD TALON TM Spin Column (Clontech). Unbound proteins 158 were removed by washing the resin with buffer A containing 10 mM imidazole. His-tagged EthA 159 bound to the resin was then gradually eluted with buffer A containing 50 and 300 mM imidazole. 160
Fractions containing approximately 90% pure EthA were combined, desalted by PD-10 column 161 (Amersham Pharmacia Biotech) and concentrated using a Vivaspin 6 (3 kDa MWCO) 162 (Sartorius). The purified protein was immediately used in cell-free assays. 163
164
In vitro metabolism of ISO by purified EthA -165
The in vitro activity of EthA on ISO was assayed as described by Vannelli and collaborators (25) 166 with minor modifications. Briefly, the reaction mixture contained 100 mM NaCl, catalase (75 U 167 ml -1 ), superoxide dismutase (75 U/ml), bovine serum albumin (0.1 mg/ml), a NADPH 168 regenerating system consisting of glucose-6-phosphate dehydrogenase (2.5 U/ml), glucose-6-169 phosphate (25 mM) and NADPH (1 mM), 40 µg of purified EthA protein, ISO dissolved in 40 µl 170 of DMSO (2 µg/ml final concentration), and 25 mM Tris-HCl buffer (pH 7.5) in a final volume 171 of 4 ml. Reactions were performed in pentaplicates. Reactions were stopped with 4 ml of 172 chloroform after 60 min of incubation at 37°C and left rocking for 30 min at room temperature. 40 µg/ml (for solubility reasons, higher concentrations of ISO could not be tested) ( Table 1) . As 240 expected, they also showed cross-resistance to ETH (MIC values > 10 µg/ml as compared to an 241 MIC of ~ 5 µg/ml for the parent strains as determined by the agar dilution method). 242
To determine whether ISO-resistance in these strains arose from the mutations in ethA, a 243 functional copy of the ethA gene carried by the multi-copy vector pVVethA was introduced into 244 each of the mutants and the MIC of ISO against the complemented mutant strains was 245 oxidation followed by an elimination) would lead to the reactive carbodiimide (4) which, in our 294 experimental setting, would be hydrolyzed into the urea derivative (5). 295
A C C E P T E D
In conclusion, LC/MS analysis of the reaction products resulting from the action of EthA 296 on ISO in vitro revealed the occurrence of stable species arising from initial oxidation processes 297 leading to reactive species. These results are in agreement with the previously reported 298 occurrence of related reactive species following incubation of ETH or TAC with EthA and with 299 the previously suggested inhibitory activity of these metabolites (6, 12, 19, 25) . 300
301

Effect of ISO activation on the synthesis of mycolic acids and unsaturated short-chain fatty acids 302
by mycobacterial cell-free extracts 303 ISO inhibits the synthesis of mycolic acids through the inhibition of (an) as yet 304 unidentified enzyme(s) and that of short-chain ∆9 mono-unsaturated fatty acids through the 305 inhibition of the ∆9 desaturase DesA3 (17-18,28). We were thus interested in determining 306 whether the in vitro activation of ISO by EthA stimulated the inhibitory effect of the drug on 307 these two metabolic pathways. To this end, two cell-free assays were designed. Mycolic acid 308 synthesis was monitored using M. bovis BCG sonicates as enzyme source and [1,2-14 C]acetic 309 acid as the radiolabeled substrate. The catalytic activity of DesA3 was measured in an assay 310 containing a partially purified form of the DesA3 protein, palmitoyl-CoA and M. smegmatis 311 membranes as a further source of substrates and co-factors for the desaturation system. As 312 expected, the addition of ISO to the first assay resulted in the inhibition of the synthesis of both 313 observations, the addition of ISO to the second assay also completely inhibited the stimulatory 315 effect of DesA3 on the in vitro synthesis of palmitoleic and oleic acids (Fig. 2B) (18) . 316
Unexpectedly however, the addition of purified EthA to these assays almost totally abolished the 317 inhibitory effect of the drug on mycolic acid, palmitoleic and oleic acid synthesis (Fig. 2) . We 318 conclude from these experiments that the addition of purified EthA to the reaction mixtures 
